Osteoporosis
Full-length parathyroid hormone is under review for osteoporosis treatment
Published in Medical Letter on the CDC and FDA, July 30th, 2006
According to a recent report from the United States, "Full-length or intact parathyroid hormone [rDNA origin] for injection (PTH [1-84], Preos, NPS Pharmaceuticals) is currently under FDA review for the treatment of postmenopausal osteoporosis. If approved, parathyroid hormone (1-84) will join teriparatide (PTH [134], Forteo, Lilly), the truncated N-terminal (1-34) form of the hormone, as the only anabolic therapies available for osteoporosis treatment."
"There are currently no published head-to-head trials comparing teriparatide and intact...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Food Poisoning
U.S. FDA issues guidance to help prevent introduction of allergens or toxins into food and feed - Newborn Screening
Use of residual dried blood spots from newborn screening programs is examined - Pneumonia Risk Factors
Severe pneumonia due to Staphylococcus aureus was linked to methicillin-resistance - Proteomics
Epstein-Barr virus nuclear antigen 2 induces Fc-receptor homolog 5 expression through CBF1 protein - Public Health
Violence against women is more likely during pregnancy than after delivery - Addiction Medicine
Assessment method affects dosage estimate in recreational ecstasy users - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
